Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Barrios

Showing results (81-90 of 183) with videos related to

Pageof 19
Sort By:
Heliyon|January 1, 2021
Modeling vegetative vigour in grapevine: unraveling underlying mechanismsInés P Hugalde, Cecilia B Agüero, Felipe H Barrios-Masias, et al.
Future Oncology (London, England)|October 21, 2022
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancerHope S Rugo, Javier Cortes, Carlos H Barrios, et al.
New Microbes and New Infections|April 26, 2018
Phenotypic and molecular characterization of <i>Klebsiella</i> spp. isolates causing community-acquired infectionsU Garza-Ramos, H Barrios-Camacho, S Moreno-Domínguez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 18, 2020
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancerS Adams, V Diéras, C H Barrios, et al.
Breast Cancer Research : BCR|February 11, 2017
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapyAntonino Musolino, Mario Campone, Patrick Neven, et al.
ESMO Open|May 29, 2025
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trialX Hu, G Curigliano, K Yonemori, et al.
Ecology and Evolution|August 28, 2025
Genetic Divergence and Isolation of the Green Sea Turtle (<i>Chelonia mydas</i>) in the Red SeaK Scott, S He, R S Hardenstine, et al.
JCO Global Oncology|January 12, 2021
Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in BrazilBruno L Ferrari, Carlos Gil Ferreira, Márcia Menezes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2015
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomaA Ravaud, C H Barrios, B Alekseev, et al.
Cancer|September 8, 2011
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinomaCarlos H Barrios, David Hernandez-Barajas, Michael P Brown, et al.
Pageof 19

Showing results (81-90 of 183) with videos related to

Sort By:
Pageof 19
Heliyon|January 1, 2021
Modeling vegetative vigour in grapevine: unraveling underlying mechanismsInés P Hugalde, Cecilia B Agüero, Felipe H Barrios-Masias, et al.
Future Oncology (London, England)|October 21, 2022
GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancerHope S Rugo, Javier Cortes, Carlos H Barrios, et al.
New Microbes and New Infections|April 26, 2018
Phenotypic and molecular characterization of <i>Klebsiella</i> spp. isolates causing community-acquired infectionsU Garza-Ramos, H Barrios-Camacho, S Moreno-Domínguez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 18, 2020
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancerS Adams, V Diéras, C H Barrios, et al.
Breast Cancer Research : BCR|February 11, 2017
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR<sup>+</sup>, HER2<sup>-</sup> breast cancer that had progressed during or after prior endocrine therapyAntonino Musolino, Mario Campone, Patrick Neven, et al.
ESMO Open|May 29, 2025
Patient-reported outcomes with trastuzumab deruxtecan in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer: results from the randomized DESTINY-Breast06 trialX Hu, G Curigliano, K Yonemori, et al.
Ecology and Evolution|August 28, 2025
Genetic Divergence and Isolation of the Green Sea Turtle (<i>Chelonia mydas</i>) in the Red SeaK Scott, S He, R S Hardenstine, et al.
JCO Global Oncology|January 12, 2021
Determinants of COVID-19 Mortality in Patients With Cancer From a Community Oncology Practice in BrazilBruno L Ferrari, Carlos Gil Ferreira, Márcia Menezes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 9, 2015
RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon α-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinomaA Ravaud, C H Barrios, B Alekseev, et al.
Cancer|September 8, 2011
Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinomaCarlos H Barrios, David Hernandez-Barajas, Michael P Brown, et al.
Pageof 19